The stock markets in both A-shares and Hong Kong experienced a significant correction on July 17th. The Shanghai Composite Index fell by 3%, dropping below the 3800-point mark, while the ChiNext Index plummeted 7.15%. The Hang Seng Index also declined by 1.78%. Amid this broad market sell-off, the biotech sector, which had shown notable recent strength, was not spared.
Stocks in the Hong Kong Stock Connect biotech segment saw extreme volatility. Seven companies, including Akeso Inc and Remegen Co., Ltd., tumbled over 10%. The dedicated biotech ETF, Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection Trading Open Ended Index Securities Inves (ETF Code: 520880), which focuses 100% on innovative drug R&D companies, experienced an intraday swing of 7.83%, closing down 6.09%—its largest single-day decline since listing. However, the fund continued to trade at a premium, indicating strong buying interest and potential capital inflows on the dip.
The A-share pharmaceutical sector, after six consecutive days of gains, abruptly reversed course. Seven stocks fell more than 10%, with Remegen Co., Ltd. leading the decline, down 15.51%. Major index constituents like Kelun Pharmaceutical Co., Ltd. and Haisco Pharmaceutical Group Co., Ltd. hit their daily down limits. The only on-exchange ETF tracking the pharmaceutical index, Huabao Pharmaceutical ETF (ETF Code: 562050), closed down 5.27%, also setting a historical record for single-day loss, halting its six-day winning streak.
What Triggered the Sell-Off?
Market analysts point to several factors. Externally, sharp volatility in overseas technology sectors directly impacted A-shares. Internally, as the semi-annual earnings verification period progresses, some companies reported growth figures that fell short of expectations. This triggered concentrated profit-taking by investors, creating a chain reaction that amplified the correction in previously high-flying sectors.
Was the Biotech Sell-Off Overdone?
The rebound in biotech stocks began in late June and had lasted for over half a month. The severe market-wide adjustment caused a sudden drop in risk appetite, likely prompting short-term traders to lock in profits. However, the overall recovery trend for the innovative drug sector may not have fundamentally reversed.
Looking at the week's performance, the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection Trading Open Ended Index Securities Inves (ETF Code: 520880) declined 3.79% on-exchange, with turnover reaching CNY 4.365 billion, marking its second-highest weekly volume on record. The continued high volume suggests sustained investor interest. The A-share pharmaceutical sector demonstrated relative resilience; the Huabao Pharmaceutical ETF (ETF Code: 562050) gained 0.41% on-exchange for the week, significantly outperforming the broader market (the Shanghai Composite fell 5.81% weekly), with its weekly turnover of CNY 204 million hitting a record high.
Fundamental Support Remains
From a fundamental perspective, positive interim earnings previews from several biotech firms validate the sector's robust growth momentum, potentially supporting future price recovery. In Hong Kong, Insilico Medicine forecasted its first-half net profit to increase by 274.48% to 305.73% year-over-year, while KeyMed Biosciences Inc. projected a net profit surge exceeding 1,600%.
In the A-share market, Haisco Pharmaceutical Group Co., Ltd. guided for an interim net profit increase of up to 575% year-over-year. Zhejiang Huahai Pharmaceutical Co., Ltd. expects growth of up to 95%, with Hybio Pharmaceutical Co., Ltd. and Allist Pharmaceuticals Co., Ltd. forecasting maximum increases exceeding 68% and 46%, respectively.
Market Outlook and Investment Tools
Assessing the current market environment, a major securities firm's healthcare research team reiterated that innovative drug stocks represent a high-value, growth-oriented asset class currently positioned at relatively low levels, aside from the AI theme. The underlying trend of improving industry fundamentals remains intact, characterized by the commercial ramp-up of core products, a vibrant business development (BD) landscape, and accelerating global commercialization of key drugs. This could pave the way for a revaluation driven by fundamental and cyclical improvements.
For investors considering accumulating core biotech assets during the dip, two key ETFs are highlighted:
Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection Trading Open Ended Index Securities Inves (ETF Code: 520880): Offers 100% exposure to innovative drug R&D companies. Its top ten holdings account for over 70% of the portfolio, emphasizing leading players. The underlying assets are Hong Kong-listed stocks, offering high volatility and T+0 settlement.
Huabao Pharmaceutical ETF (ETF Code: 562050): The only ETF tracking the pharmaceutical index in the market, featuring a unique allocation of "72% innovative drugs + 22% traditional Chinese medicine." This blend combines the high-growth potential of innovative drugs with the high-dividend characteristics of TCM stocks.
Comments